Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Status:
Completed
Trial end date:
2017-04-21
Target enrollment:
Participant gender:
Summary
Patients diagnosed with malignant glioma who are receiving temozolomide will be accrued in
this open label, phase 2, randomized single institution trial of aprepitant in combination
with ondansetron versus ondansetron alone for the prevention of acute and delayed
chemotherapy-induced nausea and vomiting (CINV). Sixty-eight (68) patients will be randomized
to each arm of the study.